Sugi Predict

Sugi Predict / Compounds / SCHEMBL309316

SCHEMBL309316

SCHEMBL309316

COc1ccc(COc2cc(Br)cc(S(C)(=O)=O)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 1/20 0.54
▸ MAOB P27338 2/20 0.48
▸ CA12 O43570 1/20 0.47
▸ CA1 P00915 1/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA7 P43166 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ FFAR1 O14842 2/20 0.45
▸ PPARG P37231 1/20 0.45
▸ PPARD Q03181 1/20 0.45
▸ PPARA Q07869 1/20 0.45
▸ APP P05067 5/20 0.45
▸ NPC1 O15118 3/20 0.44
▸ RAB9A P51151 3/20 0.44
▸ POLB P06746 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ MMP2 P08253 1/20 0.43
▸ ADAM17 P78536 1/20 0.43
▸ SMPD1 P17405 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL309240 0.86 MAOB (0.54) BRD4MAOBCA12CA1CA2
SCHEMBL310367 0.83 MAOB (0.60) MAOBFFAR1APPNPC1RAB9A
SCHEMBL24156677 0.80 SMN1; SMN2 (0.39) POLBSMN1; SMN2
SCHEMBL30253355 0.80 SMN1; SMN2 (0.39) POLBSMN1; SMN2
SCHEMBL7240044 0.77 MAOB (0.53) MAOBFFAR1APPNPC1RAB9A
SCHEMBL3930569 0.77 APP (0.63) MAOBAPPNPC1RAB9APOLB
SCHEMBL7240384 0.77 MAOB (0.53) MAOBFFAR1APPNPC1RAB9A
SCHEMBL3639311 0.76 NPC1 (0.66) MAOBFFAR1PPARGPPARDPPARA
SCHEMBL13690355 0.76 MAOB (0.49) MAOBFFAR1APPNPC1RAB9A
SCHEMBL16064448 0.76 LOX (0.48) MAOBCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20220315601-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2022-10-06 — — US disclosed
EP-3640241-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-09-28 — — EP disclosed
CN-108558889-B Bromodomain inhibitors 赛尔基因昆蒂赛尔研究公司 2021-11-05 — — CN disclosed
US-10941160-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2021-03-09 — — US disclosed
US-20200148703-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-05-14 — — US disclosed
EP-3640241-A1 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2020-04-22 — — EP disclosed
US-10562915-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-02-18 — — US disclosed
WO-2015058160-A1 BROMODOMAIN INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2015-04-23 — — WO disclosed
US-20150111885-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2015-04-23 — — US disclosed
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 — — US disclosed
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 — — US disclosed
US-8093253-B2 Leukotriene B4 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-01-10 — — US disclosed
EP-2250150-A1 LEUKOTRIENE B4 INHIBITORS F. Hoffmann-La Roche AG (CH) 2010-11-17 — — EP disclosed
WO-2009109483-A1 LEUKOTRIENE B4 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 — — WO disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 — — US disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 — — US disclosed
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS DOMINIQUE ROMYR 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227603-A1 LEUKOTRIENE B4 INHIBITORS LTB4R2, LTB4R, LTC4S BRD4 2322/4885MAOB 112/4885CA12 4223/4885
US-10562915-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 BRD4 5/4885MAOB 3360/4885CA12 3491/4885
US-20220315601-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD4 5/4885MAOB 3360/4885CA12 3491/4885
US-20150111885-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD4 5/4885MAOB 3360/4885CA12 3491/4885
US-10941160-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 BRD4 5/4885MAOB 3360/4885CA12 3491/4885
US-20200148703-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 BRD4 5/4885MAOB 3360/4885CA12 3491/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 BRD4 5/4885MAOB 3360/4885CA12 3491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.